Exelixis of San Francisco said it licensed genetic technology to enable advanced analysis in the laboratory mouse.
The licensed technology, which was originally developed by William Dove of the Wisconsin Alumni Research Foundation, elucidates gene function and will possibly allow Exelixis to identify key disease genes or drug targets that would be difficult to identify with alternative mouse technologies, the company said.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
